Provided by Tiger Trade Technology Pte. Ltd.

Teva Pharmaceutical

28.74
-1.0400-3.49%
Post-market: 28.960.2200+0.77%17:49 EDT
Volume:5.57M
Turnover:160.71M
Market Cap:33.48B
PE:23.75
High:29.52
Open:29.40
Low:28.63
Close:29.78
52wk High:37.35
52wk Low:12.47
Shares:1.17B
Float Shares:1.14B
Volume Ratio:0.80
T/O Rate:0.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.21
EPS(LYR):1.21
ROE:20.79%
ROA:6.17%
PB:4.23
PE(LYR):23.75

Loading ...

Corcept Provides Update on Patent Dispute With Teva Pharmaceuticals

THOMSON REUTERS
·
Feb 20

Truist Financial Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)

TIPRANKS
·
Feb 19

Teva Pharmaceuticals Is Maintained at Buy by Truist Securities

Dow Jones
·
Feb 18

BRIEF-Viking Global Reports Share Stake In Amazon, Raises In Boeing & T-Mobile, Dissolves In BlackRock

Reuters
·
Feb 18

Truist Securities Adjusts Teva Pharmaceutical Industries Price Target to $42 From $38, Maintains Buy Rating

MT Newswires Live
·
Feb 18

Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients

Benzinga_recent_news
·
Feb 17

Teva and Sanofi’s duvakitug Phase 2b data shows efficacy in colitis and Crohn’s

TIPRANKS
·
Feb 17

BRIEF-Sanofi Says Phase 2B Study Shows duvakitug Efficacious In Ulcerative Colitis, Crohn's Disease

Reuters
·
Feb 17

Teva: Duvakitug Was Well Tolerated and Safety Was Consistent With Induction Study

THOMSON REUTERS
·
Feb 17

Teva and Sanofi’s Duvakitug Phase 2B Maintenance Data Demonstrated Clinically Meaningful Durable Efficacy in Ulcerative Colitis and Crohn’s Disease

THOMSON REUTERS
·
Feb 17

Teva (TEVA) Is Down 5.2% After Returning To Profitability On Innovation-Led Revenue Shift – What’s Changed

Simply Wall St.
·
Feb 12

Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Recent Share Price Momentum And Biosimilar Growth Hopes

Simply Wall St.
·
Feb 10

Teva Pharmaceuticals Is Maintained at Buy by Goldman Sachs

Dow Jones
·
Feb 10

Teva price target raised to $45 from $36 at Goldman Sachs

TIPRANKS
·
Feb 09

Teva’s Sustainability Disclosures Face Rising Legal and Investor Risk Amid Global Compliance Demands

TIPRANKS
·
Feb 04

The Druckenmiller Connection: Meet the Man Behind Bessent and Warsh -- Barrons.com

Dow Jones
·
Feb 02

Teva (TEVA) Is Up 7.1% After 2025 Earnings Highlight Branded-Drugs Momentum And Pipeline Progress

Simply Wall St.
·
Feb 01

Is Teva Pharmaceutical Industries (TEVA) Still Attractive After A 92% One-Year Share Price Surge

Simply Wall St.
·
Jan 31

Teva Pharmaceuticals Is Maintained at Overweight by Barclays

Dow Jones
·
Jan 31

Teva price target raised to $38 from $35 at Barclays

TIPRANKS
·
Jan 30